Breast Adenocarcinoma Clinical Trials

14 recruiting

Breast Adenocarcinoma Trials at a Glance

17 actively recruiting trials for breast adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Hangzhou, Jacksonville, and Los Angeles. Lead sponsors running breast adenocarcinoma studies include Mayo Clinic, Second Affiliated Hospital, School of Medicine, Zhejiang University, and Centre Paul Strauss.

Browse breast adenocarcinoma trials by phase

Treatments under study

About Breast Adenocarcinoma Clinical Trials

Looking for clinical trials for Breast Adenocarcinoma? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Breast Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Breast Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 2

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+2 more
City of Hope Medical Center36 enrolled1 locationNCT06538389
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Estrogen Receptor-Positive Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+4 more
Mayo Clinic25 enrolled1 locationNCT06401889
Recruiting
Phase 1

Study of 68Ga-R10602

Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast CancerHormone Receptor Positive Breast Adenocarcinoma
Radionetics Oncology36 enrolled6 locationsNCT06745804
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Not Applicable

Preoperative Radiation Therapy and Immediate Breast Reconstruction

Breast CarcinomaBreast NeoplasmsCancer+2 more
Cancer Research Antwerp180 enrolled6 locationsNCT06739655
Recruiting

A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing

Breast CancerBreast Adenocarcinoma
National and Kapodistrian University of Athens2,000 enrolled13 locationsNCT07389408
Recruiting
Phase 4

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+2 more
University of Washington68 enrolled1 locationNCT05183828
Recruiting
Phase 1

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Recurrent Breast CarcinomaInvasive Breast Carcinoma+2 more
Mayo Clinic54 enrolled1 locationNCT04521764
Recruiting
Not Applicable

Effects of Chemotherapy Treatment on Metaboreflex, Mechanoreflex, and Baroreflex Function: PROTECT-08B Study

Breast Adenocarcinoma
Centre Paul Strauss24 enrolled1 locationNCT07069790
Recruiting
Phase 1Phase 2

Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy

Breast Adenocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University96 enrolled1 locationNCT06596018
Recruiting

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+3 more
Mayo Clinic230 enrolled1 locationNCT04517838
Recruiting
Not Applicable

Definitive Radiation Therapy for Inoperable Breast Cancer

Breast CancerBreast Adenocarcinoma
Alexander Stessin30 enrolled1 locationNCT07122713
Recruiting
Phase 2

TRUDI: TDXD+Durva in HER2+/Low IBC

Breast CancerInvasive Breast CancerHER2-positive Breast Cancer+2 more
Filipa Lynce, MD63 enrolled3 locationsNCT05795101
Recruiting

Personalization of External Beam Radiation Therapy in Localised Tumours

Breast AdenocarcinomaProstate Cancer (Adenocarcinoma)
European Institute of Oncology35 enrolled1 locationNCT07047495
Recruiting
Phase 2

Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer

Breast Adenocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University74 enrolled1 locationNCT06671262
Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Breast AdenocarcinomaBreast Cancer Stage IV
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano3,500 enrolled24 locationsNCT06805812